Mortality Risk Assessment and the Role of Thrombolysis in Pulmonary Embolism
Section snippets
Defining High-Risk PE
Acute PE is not universally life threatening, but rather covers a wide spectrum of clinical severity and death risk. In various studies, early (30-day or in-hospital) mortality rates were reported to range between less than 1% and well over 50%, mostly depending on the baseline clinical profile of the patients studied.4, 5, 6, 7, 8, 9, 14
It is now well established that the principal pathophysiological factor that determines disease severity and consequently the patients’ clinical course and
Risk-Adjusted Diagnostic Approach to PE
Numerous multistep algorithms have been proposed and prospectively validated for the diagnostic workup of normotensive patients with suspected PE. Recent algorithms are based on the superior diagnostic sensitivity and specificity of multidetector-row computed tomography (MDCT)/pulmonary angiography, and its ability to confirm and in particular safely exclude PE without the need for venous ultrasound as an intermediate step.25, 29, 30, 31 On the other hand, management of the hemodynamically
Benefits of Thrombolysis in Acute PE
In view of the high early mortality and complication risk associated with high-risk PE,5, 26, 27 existing guidelines25, 35 and the overwhelming majority of experts and clinicians agree that patients who present with persistent arterial hypotension or shock are in need of immediate pharmacologic or mechanical recanalization of the occluded pulmonary arteries.
In early reports dating back to 1971, streptokinase infusion over 72 hours resulted in a significant reduction of systolic pulmonary artery
Potential Risks of Thrombolysis
Pooled data from controlled thrombolysis trials in PE, which either compared thrombolysis with heparin alone or different thrombolytic regimens with each other,37, 41, 43, 47, 48, 49, 50, 51, 52, 53, 54 revealed a 13% cumulative rate of major bleeding and a 1.8% rate of intracranial/fatal hemorrhage.55 Major hemorrhage has been less common in the most recent (and largest) trials,44, 47 in agreement with the notion that thrombolysis-related bleeding rates may be lower when noninvasive imaging
Current Use of Thrombolysis in Acute PE with High Risk for Early Death
Although the angiographic and hemodynamic benefits of thrombolysis are unequivocal, at least over the short term, the (presumed) favorable effects of thrombolysis on the clinical outcome of patients with PE have thus far not been convincingly demonstrated. As already mentioned, this partly relies on the fact that the majority of thrombolysis trials in PE were too small to address clinical end points. Even the most recent and largest of these trials failed to show a survival benefit,44, 47
Potential Role of Thrombolysis in Intermediate-Risk (Submassive) PE
At present, low molecular weight heparin or fondaparinux is considered adequate treatment for most normotensive patients with pulmonary embolism, whereas routine thrombolysis is generally not recommended as a first-line therapeutic option.25, 35 However, the results of the most recent randomized thrombolysis trial47 can be interpreted as indicating that early thrombolysis may be considered in selected patients with “nonmassive,” non-high-risk PE including, for example, those with comorbidities
Thrombolysis in Current and Emerging Concepts of PE Management
Experts and recently updated guidelines agree that thrombolysis is indicated patients with acute PE who are at high risk for early death, that is, in patients presenting with arterial hypotension and shock or refractory hypoxemia. On the other hand, heparin (unfractionated or low molecular weight) or fondaparinux is adequate treatment for most normotensive patients with PE (see Fig. 1). Recombinant tissue plasminogen activator (alteplase), given as a 100-mg infusion over 2 hours, is considered
References (96)
- et al.
Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
Lancet
(1999) - et al.
Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry
J Am Coll Cardiol
(1997) - et al.
Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism
Chest
(1998) - et al.
Determinants of right ventricular function and hemodynamics after pulmonary embolism
Chest
(1974) - et al.
The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease
Am J Cardiol
(1971) - et al.
Platelet activation in acute pulmonary embolism
J Thromb Haemost
(2007) - et al.
Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy
Chest
(1995) - et al.
Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial
Lancet
(2008) - et al.
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry
J Am Coll Cardiol
(2003) - et al.
Combined clot fragmentation and aspiration in patients with acute pulmonary embolism
Chest
(2008)
Mechanical catheter intervention in massive pulmonary embolism: proof of concept
Chest
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism
Chest
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolismPlasminogen activator Italian multicenter study 2
J Am Coll Cardiol
Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion
Lancet
Comparison of alteplase versus heparin for resolution of major pulmonary embolism
Am J Cardiol
Thrombolytic therapy for pulmonary embolismFrequency of intracranial hemorrhage and associated risk factors
Chest
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolismA randomized controlled multicenter trial
Chest
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial
J Am Coll Cardiol
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trialThe European Cooperative Study Group for Pulmonary Embolism
J Am Coll Cardiol
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism
Lancet
Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry
Chest
Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism
Am J Med
Management of unsuccessful thrombolysis in acute massive pulmonary embolism
Chest
Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism
Am J Cardiol
Treatment of right heart thromboemboli
Chest
Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up
J Am Coll Cardiol
Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysisAn international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group
Chest
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism
Am Heart J
Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism
Thromb Res
Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate
Am Heart J
Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism
Am J Cardiol
Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis
Chest
Tenecteplase can be given to patients with intermediate-risk pulmonary embolism—but should it?
Thromb Res
The fatty acid transport function of fatty acid-binding proteins
Biochim Biophys Acta
Fatty acid-binding proteins as plasma markers of tissue injury
Clin Chim Acta
Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism
Clin Chim Acta
Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism
J Am Coll Cardiol
Thrombolysis for hemodynamically stable patients with pulmonary embolism: still searching for the intermediate-risk group
Thromb Res
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study
Arch Intern Med
A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolismThe Worcester DVT Study
Arch Intern Med
The epidemiology of venous thromboembolism
Circulation
Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolismResearch Committee of the British Thoracic Society
Lancet
The clinical course of pulmonary embolism
N Engl J Med
Weekend versus weekday admission and mortality after acute pulmonary embolism
Circulation
Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry
Circulation
Venous thromboembolism (VTE) in EuropeThe number of VTE events and associated morbidity and mortality
Thromb Haemost
The changing pattern of venous thromboembolic disease
Haemostasis
Cited by (24)
Management dilemmas in acute ischemic stroke and concomitant acute pulmonary embolism: Case series and literature review
2021, eNeurologicalSciCitation Excerpt :In scenarios in which the risk of rt-PA exceeds its benefits, MT and endovascular therapy with stent retriever should be highly considered [24]. In massive PE, there is clear indication to reverse right ventricular pressure overload and potential fulminant cardiac failure with emergent recanalization of the pulmonary vasculature by either mechanical thrombolysis or pharmacological thrombolysis [24,25]. Therefore, in large AIS cases and high risk of hemorrhagic conversion, the former option (IV rt-PA) should be considered immediately.
Perspectives of patients and health professionals on important factors influencing rehabilitation following acute pulmonary embolism: A multi-method study
2020, Thrombosis ResearchCitation Excerpt :Across Europe, Canada and the USA, more than 500,000 people are diagnosed with pulmonary embolism (PE) every year [1,2], a serious event with a reported 30-day mortality of up to 30% [3,4].
A systematic review and pooled analysis of CPR-associated cardiovascular and thoracic injuries
2014, ResuscitationCitation Excerpt :In one study of 43 patients, no increase in bleeding complications was observed in patients given thrombolysis during CPR.90 Thrombolytic therapy may also be used to treat acute massive pulmonary embolism (PE) manifested by hemodynamic instability or right ventricular failure.68,91 In an analysis of 66 patients with cardiac arrest due to massive PE, no significant difference in major bleeding events was observed92 and CPR duration greater than 10 min did not increase the incidence of major bleeding complications.92
Prevention of hospital-associated venous thromboembolism — Insight from the Getting It Right First Time thrombosis survey in England
2023, British Journal of HaematologyApplication value of surgical pulmonary embolectomy in the treatment of acute pulmonary embolism
2022, Chinese Journal of Anatomy and ClinicsPopliteal Venous Aneurysm With Pulmonary Embolism: A Case Report
2021, Vascular and Endovascular Surgery
A version of this article originally appeared in Clinics in Chest Medicine, 31:4.